Navigation Links
Core Informatics Delivers Enterprise Core LIMS Installation to BioRelix Pharmaceuticals
Date:4/29/2008

BRANFORD, Conn., April 29 /PRNewswire/ -- Core Informatics announces that it has delivered an installation of their Enterprise Core LIMS product to BioRelix Pharmaceuticals of New Haven, CT. BioRelix, which started laboratory operations in late 2007, recognized the need to establish a strong data management infrastructure from the beginning. After conducting an extensive survey of the LIMS marketplace, BioRelix choose the Core LIMS.

"After our evaluation it became very clear that the Core LIMS was the best product for our needs," said Ken Blount, Director of Biology for BioRelix. "Their product provides us with an opportunity to manage data for our entire drug discovery process in a single enterprise wide system."

One of the benefits of the Core LIMS is its component-based architecture, which allows customers to choose only the components of their system that are required to meet their current needs. "As BioRelix grows and their needs change to require, for example, in-life studies, they can purchase additional components for the Core LIMS to enable that growth," said James Gregory, Chief Software Architect of Core Informatics.

About Core Informatics

Core Informatics is a software company focused on delivering state of the art, fully customized Laboratory Information Management Systems (LIMS) to customers in a variety of industries. Their signature product, The Core LIMS, is a web-based LIMS that features a component-based architecture, which provides its clients the freedom to pick and choose only the functionality relevant to their specific research. The company provides its products via three modes of delivery: LIMS appliances, hosted LIMS and enterprise LIMS.

For more information about Core Informatics, please visit http://www.corelims.com.

About BioRelix Pharmaceuticals

BioRelix Pharmaceuticals, Inc. is a drug discovery and development company focused on identifying new anti-infective drug treatments. BioRelix is building a portfolio of anti-infective products based on novel patented RNA targets, termed RiboSwitches, which were identified in the laboratory of BioRelix co-founder, Ronald Breaker Ph.D., Howard Hughes Investigator and Henry Ford II Professor at Yale University. BioRelix investors include CHL Medical Partners, New Leaf Venture Partners, Aisling Capital, Novartis Venture Fund, Elm Street Ventures and Alexandria Real Estate Equities.

For more information about BioRelix Pharmaceuticals, please visit http://www.biorelix.com.


'/>"/>
SOURCE Core Informatics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Malaysia Genome Institute Advances Bioinformatics Research Using SGI Technology
2. BioInformatics, LLC Studies Trade Show Exhibition Strategies in the Life Science Market
3. Core Informatics Completes Successful LIMS Implementation for Progenics Pharmaceuticals
4. IC Sciences Launches ICS Alliance to Advance Development and Adoption of Informatics Instruments for Next Generation Healthcare
5. Perceptive Informatics Improves Clinical Site Monitoring Access and Flexibility With Portable USB Drive Capability
6. CompareNetworks Media Group Delivers CME/CE Through Acuity Medical Education
7. Nikon Instruments New NIS-Elements C Delivers Comprehensive Confocal and Widefield Imaging Capabilities in Single Unifying Software Platform
8. Millennium Over-Delivers on 2007 Goals and Financial Guidance
9. NIOXIN(R) Delivers the Future to Scalp and Hair Care, Introduces the First Genetic Test to Determine the Likelihood of Hair Loss
10. Vital Images Releases Next Generation Enterprise-Wide Solutions Featuring Vitrea(R) 4.0 and ViTALConnect(R) 4.1
11. Neogen Acquires Kane Enterprises
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Regular discussions on a range of subjects ... the two entities said Poloz. Speaking at a ... , he pointed to the country,s inflation target, which ... "In certain areas ... have common economic goals, why not sit down and address ...
(Date:6/24/2016)... NC (PRWEB) , ... June 24, 2016 , ... Researchers ... the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are ... to read it now. , Diagnostic biomarkers are signposts in the blood, lung ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... June 23, 2016 Houston Methodist Willowbrook ... Cy-Fair Sports Association to serve as their official ... Houston Methodist Willowbrook will provide sponsorship support, athletic ... with association coaches, volunteers, athletes and families. ... Cy-Fair Sports Association and to bring Houston Methodist ...
Breaking Biology Technology:
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
(Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
Breaking Biology News(10 mins):